Demência com corpos de Lewy
abordagem clínica e terapêutica
DOI:
https://doi.org/10.34024/rnc.2005.v13.8842Palavras-chave:
Demência com corpos de Lewy, Doença de Parkinson, Inibidores de colinesterase, NeurolépticosResumo
A demência com corpos de Lewy (DCL) é uma das principais causas de demência, sendo parte de um espectro clínico de doenças com inclusões neuronais denominadas corpos de Lewy, que inclui a doença de Parkinson. Do ponto-de-vista clínico, a DCL caracteriza-se por flutuação cognitiva, alucinações visuais e parkinsonismo espontâneo. O tratamento farmacológico baseia-se no emprego de inibidores de colinesterase, objetivando atenuar os déficits cognitivos e as alterações comportamentais. O emprego de neurolépticos deve ser evitado face à grande sensibilidade desses pacientes aos mesmos
Downloads
Métricas
Referências
Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidenced based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143-1153.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington: American Psychiatric Association, 1994.
Snowden JS, Neary D, Mann DM. Frontotemporal dementia. Br J Psychiatry 2002; 180: 140-143.
Cummings JL. Alzheimer’s disease. N Engl J Med 2004; 351: 56-67.
Herrera E, Caramelli P, Silveira AS, Nitrini R. Epidemiologic survey of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord 2002; 16: 103-108.
Takada LT, Caramelli P, Radanovic M, et al. Prevalence of potentially reversible dementias in a dementia outpatient clinic of a tertiary university-affiliated hospital in Brazil. Arq Neuropsiquiatr 2003; 61: 925-929.
McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19-28.
Okazaki H, Lipkin LE, Aranson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neurol Pathol Exp Neurol1961; 20: 237-244.
Greicius MD, Geschwind MD, Miller BL. Presenile dementia syndromes: an update on taxonomy and diagnosis. J Neurol Neurosurg Psychiatry 2002; 72: 691-700.
Aarsland D, Ballard CG, Halliday G. Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004; 17: 137-145.
McKeith I, Mosimann UP. Dementia with Lewy bodies and Parkinson’s disease. Parkinsonism Rel Disord 2004; 10: s15-s18.
McKeith I, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the the consortium on DLB international workshop. Neurology 1996; 47: 1113-1124.13. McKeith I, Ballard GG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000; 54: 1050-1058.
Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391-403.
Stebbins GT, Goetz CG, Carillo MC, et al. Altered cortical visual processing in PD with hallucinations: a fMRI study Neurology 2004; 63: 1409-1416.
Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry 2004; 161: 843-849.
Horimoto Y, Matsumoto M, Nakazawa H, et al. Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson’s disease with dementia. J Neurol Sci 2003; 216: 105-108.
Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2001; 70: 483-488.
Teixeira-Jr AL, Cardoso F. Neuropsiquiatria dos núcleos da base: uma revisão. J Bras Psiquiatr 2004; 53: 153-158.
Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol 2003; 2: 229-237.
Walker Z, Costa DC, Walker RW, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic ligand. J Neurol Neurosurg Psychiatry 2002; 73: 134-140.
O’Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61: 919-925.
McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036.
Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy Bodies: an openlabel trial. Int Psychogeriatr 2001; 13: 199-205.
Samuel W, Caligiuri M, Galasko D, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies. Int J Geriatr Psychiatry 2000; 15: 794-802.
Aarsland D. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-712.
Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509-2518.
Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340: 757-763.
Wint DP, Okun MS, Fernandez HH. Psychosis in Parkinson’s disease. J Geriatr Psychiatry Neurol 2004; 17: 127-136.
Teixeira-Jr AL, Cardoso F. Tratamento inicial da doença de Parkinson. Revista Neurociências 2004; 12: 146-151.
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2005-03-31
Português
English
Español
